A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaKonstantinos Tzelepis, Kosuke Yusa, Sarah A. Teichmann et al.|Cell Reports|2016Cited by 834
Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Ing Soo Tiong et al.|Blood|2023Cited by 65
The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemiaHannah Lawson, Kamil R. Kranc, James P. Holt‐Martyn et al.|Nature Cancer|2024Cited by 40
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Ho Pui Jeff Lam et al.|Blood Neoplasia|2024Cited by 36
Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesisMalgorzata Gozdecka, George S. Vassiliou, Monika Dudek et al.|Nature|2025Cited by 34